Last Updated on October 17, 2024 by The Health Master
Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of C-19 positive patients.
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
To read more articles on Natco Pharma, click here
Patients treated with Molnupiravir achieved response within five days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
NATCO is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients. “Compassionate use” approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug.
The company is ready to launch the product this month if approval is given.
Also read:
Bharat Biotech seeks DCGI’s nod to extend shelf life of Covaxin
IISER develops affordable Oxygen Concentrator
4 arrested for black marketing Remdesivir Injection
Lupin, Sun, Jubilant recall generic medicines in US
Govt exempts customs duty on C-19 vaccine, Oxygen and related equipment
Pharma firms ramp up Remdesivir output
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
